Highlights on Better Therapies for Melanoma

 

Related Videos (117)

In this video, Lynn Schuchter, MD, Chief, Division of Hematology/Oncology at Penn Medicine reviews the latest advances in the treatment of melanoma, including ipilimumab, nivolumab, Anti­PD1 monoclonal antibody MK­3475, dabrafenib and trametinib. Penn's Melanoma program has been recognized by the NCI as "outstanding," the highest rating possible for a cancer research program, and one signifying excellence in overall program quality, representation of relevant scientific disciplines, translation of new findings to the clinical setting, conduction of clinical trials, interaction of researchers, and caliber of program members and leadership.

 

Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®